Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (62)

I-005Ludovica Aiello

Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator

Wednesday 10:20-11:50

I-019Annabelle Ballesta

Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study

Wednesday 10:20-11:50

I-023Imke Bartelink

Enabling Tyrosine Kinase Inhibitor Precision Medicine through PET-Guided Physiologically-Based Pharmacokinetic Modeling

Wednesday 10:20-11:50

I-038Myriam Briki

Model-based meta-analysis of individual patient data from three independent datasets for the characterization of intravenous 5-fluorouracil population pharmacokinetics

Wednesday 10:20-11:50

I-049Elio Campanile

Supporting the development and optimization of mRNA-encoded therapeutics through a multiscale Physiologically Based Pharmacokinetic (PBPK) platform

Wednesday 10:20-11:50

I-054Daniel Centanni

Pharmacometric modeling to capture the time varying pharmacokinetics of PEG-asparaginase in acute lymphoblastic leukemia: A multi-protocol analysis from Nordic and Baltic countries

Wednesday 10:20-11:50

I-055Maddalena Centanni

Population pharmacodynamic characterization of automatically classified circulating tumor cells and vesicles and their relationship to survival in metastatic colorectal cancer patients

Wednesday 10:20-11:50

I-056Marc Cerou

A novel drug disease model in oncology to evaluate benefit-risk balance of tusamitamab ravtansine monotherapy

Wednesday 10:20-11:50

I-057Anne Chain

Population Pharmacokinetic and Exposure Response Analysis of Belzutifan in Advanced Renal Cell Carcinoma

Wednesday 10:20-11:50

I-062Chengcong CHEN

Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer

Wednesday 10:20-11:50

I-077Miné De Kock

Semi-mechanistic PK model development of Sabestomig for Dose Selection

Wednesday 10:20-11:50

I-083Oleg Demin

Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis

Wednesday 10:20-11:50

I-084Oleg Demin Jr

Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling

Wednesday 10:20-11:50

I-094Vito Dozio

Population PK and exposure-response modeling to support the design of trials with Debio 0123, a WEE1 inhibitor, in cancer patients

Wednesday 10:20-11:50

II-003Anna Gebhard

Pharmacokinetic–pharmacodynamic modeling and treatment simulation of maintenance therapy for childhood acute lymphoblastic leukemia

Wednesday 15:20-16:50

II-004Eva Germovsek

A semi-mechanistic model of preclinical VSV-GP(-Luc) viral dynamics in blood and tumour

Wednesday 15:20-16:50

II-009Antonio Goncalves

Operating characteristics of TGI metrics to support early Phase Ib decisions in unresectable hepatocellular carcinoma patients based on an historical Phase III study (IMbrave150)

Wednesday 15:20-16:50

II-019Ikhlas Guermi

Development of a pharmacokinetic-pharmacodynamic model to describe blood hepcidin levels in patients with myelofibrosis and assess target engagement of zilurgisertib, an ALK2 inhibitor

Wednesday 15:20-16:50

II-052Alberto Ippolito

PKPD model evaluating the ideal interplay between the PK and mechanism of activation of conditionally activated molecules

Wednesday 15:20-16:50

II-053Khalid Iqbal

A review of population PK and exposure-response models reported in FDA oncology submission documents

Wednesday 15:20-16:50

II-060SEONGMEE JEONG

Model informed dosage regimen optimization of anti-CD47 antibody using target-mediated drug disposition model.

Wednesday 15:20-16:50

II-075Fenja Klima

Quantifying the impact of CYP2D6 allele activity on Z-endoxifen formation leveraging the multi-study CEPAM database: Towards treatment optimisation of tamoxifen

Wednesday 15:20-16:50

II-077

Population Pharmacokinetic/Pharmacodynamic Modelling of Cytokine Releasing Syndrome (CRS) Events during T cell Engager Therapy

Wednesday 15:20-16:50

II-096Apolline Lefevre

Uncoupling tumor cell killing and cytokine release following T-cell engager administration with a mechanistic PKPD model

Wednesday 15:20-16:50

II-107Han Liu

Comparison between multistate and parametric time-to-event models for analysis of progression-free-survival (PFS) and overall survival (OS) in oncology trials

Wednesday 15:20-16:50

II-110Sarah Lobet

Revealing the complexity of monoclonal antibodies exposure-response relationship in metastatic colorectal cancer patients while mitigating confounding factors

Wednesday 15:20-16:50

III-009Mathilde Marchand

Comparison of tumor dynamics models and tumor growth inhibition metrics in support of decisions in early Phase Ib/II clinical oncology studies

Thursday 09:50-11:20

III-019Anna Mc Laughlin

Model-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2

Thursday 09:50-11:20

III-022Assil MERLAUD

To quantify the association between tumor dynamics and overall survival across cancers: a Bayesian meta-analysis

Thursday 09:50-11:20

III-024Anna Mishina

A comparative benchmark study of empirical tumor size models in NSCLC clinical data

Thursday 09:50-11:20

III-033Veronika Musatova

Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371

Thursday 09:50-11:20

III-034Goutam Nair

Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer

Thursday 09:50-11:20

III-039Linh Nguyen Phuong

Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors

Thursday 09:50-11:20

III-055Orestis Papatryfonos

Modelling of tumour growth with respect to the use of anti-cancer agents

Thursday 09:50-11:20

III-059Blaise Pasquiers

Translational modelling of tumor growth inhibition and treatment resistance for a molecule targeting apoptosis pathway

Thursday 09:50-11:20

III-063Sophie Peigné

Population pharmacokinetic analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate

Thursday 09:50-11:20

III-068Yuan Pétermann

Population pharmacokinetic model of encorafenib and binimetinb in real life settings

Thursday 09:50-11:20

III-075Antoine Pitoy

Estimation of phase III trial outcome in oncology using joint models of longitudinal biomarker and time-to-event data

Thursday 09:50-11:20

III-076Vikram Prabhakar

A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications

Thursday 09:50-11:20

III-078Alicja Puszkiel

Impact of resting energy expenditure on nivolumab pharmacokinetics and survival in metastatic non-small cell lung cancer patients

Thursday 09:50-11:20

III-079Luyuan Qi

A generic modeling framework for dose regimen optimization and patient selection in radioligand therapy

Thursday 09:50-11:20

III-082Chetan Rathi

Translational PK-Tumor Growth Inhibition (TGI) modeling of type 1 PRMT and PRMT5 inhibitor combination to predict clinical response

Thursday 09:50-11:20

III-091Pascale Rietveld

The effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634

Thursday 09:50-11:20

III-095François Riglet

Successful Establishment of Optimal Biological Dose (OBD) through PK/PD Modeling of BCL2/BIM Complex Disruption in Clinical Trials using a BCL-2 Inhibitor.

Thursday 09:50-11:20

III-097Christelle Rodrigues

Optimizing the Dose Escalation of a new anti-CD73 monoclonal antibody for target Inhibition: A Comprehensive Preclinical and Clinical Modelling Approach

Thursday 09:50-11:20

III-100Davide Ronchi

Translational modeling of tumor response to treatment: bridging preclinical to clinical studies

Thursday 09:50-11:20

III-110Adriana Savoca

Integration of clinical data and mechanistic model simulations highlights key parameters for design and selection of successful ADCs

Thursday 09:50-11:20

IV-003Alejandro Serrano Alcaide

Relationship between tumor growth and Treg activation status to optimize a previously published Immune oncology framework

Thursday 15:00-16:30

IV-012Pooneh Soltantabar

Elranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from MagnetisMM Studies

Thursday 15:00-16:30

IV-013Meemansa Sood

Lutathera dose determination and justification in adolescents via population PK and dosimetry modeling and simulation

Thursday 15:00-16:30

IV-014Tomas Sou

Population PK/PD modelling to evaluate the effect of siremadlin and disease progression on platelet dynamics in haematological malignancies

Thursday 15:00-16:30

IV-028Sung Taewook

Optimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment

Thursday 15:00-16:30

IV-029Zhiyuan Tan

Model-informed pazopanib dose optimization in real-world cancer patients

Thursday 15:00-16:30

IV-032David Ternant

Unveiling a “predator/prey” interplay of anti-CD19 CAR T-Cells and their targets in Relapsed/refractory DLBCL patients

Thursday 15:00-16:30

IV-033Adrien Tessier

Joint Modeling Of Longitudinal Circulating Tumor DNA And Survival In Metastatic Colorectal Cancer: A Promise Of Early Prediction Of Response In Oncology?

Thursday 15:00-16:30

IV-036Hoai-Thu Thai

A joint modeling approach leveraging intravenous data to support dose selection of subcutaneous isatuximab in combination with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma

Thursday 15:00-16:30

IV-053Tamara van Donge

Middle-out physiologically-based pharmacokinetic modeling to support pediatric dosing recommendation for alectinib, an ALK tyrosine kinase receptor inhibitor

Thursday 15:00-16:30

IV-062Scott Van Wart

Population Pharmacokinetic (PK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Serum M-Protein in an Ongoing Phase 1/2 Study of Modakafusp Alfa in Patients with Relapsed/Refractory Multiple Myeloma

Thursday 15:00-16:30

IV-092Yin Cheong Wong

Population pharmacokinetic/pharmacodynamic modeling to evaluate target suppression in patients with advanced solid tumors by ginisortamab, an anti-gremlin-1 monoclonal antibody

Thursday 15:00-16:30

IV-101Simone Zannoni

The impact of weekend dosing holidays on the evaluation of the sterilizing efficacy of different 4-drug combinations in a relapsing mouse model of Mycobacterium tuberculosis infection using a logistic Emax model

Thursday 15:00-16:30

IV-105Stefan Zeiser

A population PK analysis of docetaxel after IV administration of CPC634 (CriPec® docetaxel) and generic docetaxel in plasma and tumor

Thursday 15:00-16:30

IV-112Kirill Zhudenkov

A model-based survival meta-analysis for indirect comparison of immune therapy efficacy in NSCLC

Thursday 15:00-16:30